Abstract
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Cytokine storm, Th17, JAK2 inhibitor, 【초록키워드】 Treatment, FDA, immune, response, Patient, inhibitor, development, profiles, high mortality, reducing mortality, JAK2, pandemic disease, effective, approved, Fedratinib, patients with SARS-CoV-2, 【제목키워드】 response, inhibitor, JAK2, Fedratinib,
【저자키워드】 COVID-19, SARS-CoV-2, Cytokine storm, Th17, JAK2 inhibitor, 【초록키워드】 Treatment, FDA, immune, response, Patient, inhibitor, development, profiles, high mortality, reducing mortality, JAK2, pandemic disease, effective, approved, Fedratinib, patients with SARS-CoV-2, 【제목키워드】 response, inhibitor, JAK2, Fedratinib,